Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advertisement
Daniel M. Geynisman, MDMuscle Invasive Urothelial Carcinoma | January 10, 2025
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
View More
Brandon TwyfordMuscle Invasive Urothelial Carcinoma | December 6, 2024
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
Kaitlyn KoskoMuscle Invasive Urothelial Carcinoma | December 6, 2024
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
Roger Li, MDMuscle Invasive Urothelial Carcinoma | December 4, 2024
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Emily MenendezMuscle Invasive Urothelial Carcinoma | December 3, 2024
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
Brandon TwyfordMuscle Invasive Urothelial Carcinoma | December 3, 2024
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
Shilpa Gupta, MDMuscle Invasive Urothelial Carcinoma | December 30, 2024
The final segment of this roundtable series addresses the future of immunotherapy combinations.
Shilpa Gupta, MDMuscle Invasive Urothelial Carcinoma | December 30, 2024
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
Shilpa Gupta, MDMuscle Invasive Urothelial Carcinoma | December 30, 2024
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
Shilpa Gupta, MDMuscle Invasive Urothelial Carcinoma | December 30, 2024
The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments.
Shilpa Gupta, MDMuscle Invasive Urothelial Carcinoma | December 30, 2024
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
Shilpa Gupta, MDMuscle Invasive Urothelial Carcinoma | December 30, 2024
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 19, 2024
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
Thomas Powles, MBBS, MRCP, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
Thomas Powles, MBBS, MRCP, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
Thomas Powles, MBBS, MRCP, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
Thomas Powles, MBBS, MRCP, MDMuscle Invasive Urothelial Carcinoma | October 17, 2024
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
Thomas Powles, MBBS, MRCP, MDMuscle Invasive Urothelial Carcinoma | October 16, 2024
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Advertisement